Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial

Lancet Infectious Diseases
Nov 2018 Volume 18 Number 11 p1161-1288  e339-e367
http://www.thelancet.com/journals/laninf/issue/current

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial
Punnee Pitisuttithum, Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, Sirintip Sricharoenchai, Jittima Dhitavat, Arom Pitisuthitham, Wanatpreeya Phongsamart, Kobporn Boonnak, Keswadee Lapphra, Yupa Sabmee, Orasri Wittawatmongkol, Mukesh Chauhan, Wassana Wijagkanalan, Greanggrai Hommalai, Librada Fortuna, Pailinrut Chinwangso, Indrajeet Kumar Poredi, Anita H J van den Biggelaar, Hong Thai Pham, Simonetta Viviani